Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVER – Continuous observation registry after vicriviroc exposure
2006-003463-31Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of vicriviroc in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS) (2 cohorts), sponsored by Merck & Co. Primary endpoints: Long-term clinical outcomes after vicriviroc exposure and Evolution of HIV viral tropism after vicriviroc discontinuation. Started May 2010; status: terminated.
02
Drugs
vicriviroc
03
Conditions
human immunodeficiency virus infection (HIV)acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on 2006-003463-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003463-31.